Showing results (381-390 of 453) with videos related to
Sort By:
Pageof 46
Bone Marrow Transplantation|January 19, 2020
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centersThomas Hueso, Thomas Gastinne, Sylvain Garciaz, et al.European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) networkC Soussain, S Choquet, M Blonski, et al.European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trialLaurence Brugières, Nathalie Cozic, Roch Houot, et al.Blood|April 24, 2024
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphomaGilles Crochet, Gloria Iacoboni, Audrey Couturier, et al.Journal of Neurology, Neurosurgery, and Psychiatry|August 5, 2021
Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applicationsDario Saracino, Karim Dorgham, Agnès Camuzat, et al.Frontiers in Neurology|August 28, 2020
Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center CohortSuzanne Lesage, Marion Houot, Graziella Mangone, et al.Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.Radiology|April 15, 2020
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin LymphomaFatima-Zohra Mokrane, Aiping Chen, Lawrence H Schwartz, et al.Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.American Journal of Hematology|February 24, 2018
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centersSylvain P Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, et al.Pageof 46